



## OPEN ACCESS

APPROVED BY  
Frontiers Editorial Office,  
Frontiers Media SA, Switzerland

## \*CORRESPONDENCE

Cécile Louveau  
✉ cecile.louveau@ghu-paris.fr  
Anton Iftimovici  
✉ anton.iftimovici@inserm.fr

## SPECIALTY SECTION

This article was submitted to  
Neurodevelopment,  
a section of the journal  
Frontiers in Neuroscience

RECEIVED 18 March 2023

ACCEPTED 20 March 2023

PUBLISHED 31 March 2023

## CITATION

Louveau C, Turtulici M-C, Consoli A, Poitou C,  
Coupaye M, Krebs M-O, Chaumette B and  
Iftimovici A (2023) Corrigendum: Prader-Willi  
syndrome: Symptoms and topiramate response  
in light of genetics.  
*Front. Neurosci.* 17:1189154.  
doi: 10.3389/fnins.2023.1189154

## COPYRIGHT

© 2023 Louveau, Turtulici, Consoli, Poitou,  
Coupaye, Krebs, Chaumette and Iftimovici. This  
is an open-access article distributed under the  
terms of the [Creative Commons Attribution  
License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or  
reproduction in other forums is permitted,  
provided the original author(s) and the  
copyright owner(s) are credited and that the  
original publication in this journal is cited, in  
accordance with accepted academic practice.  
No use, distribution or reproduction is  
permitted which does not comply with these  
terms.

# Corrigendum: Prader-Willi syndrome: Symptoms and topiramate response in light of genetics

Cécile Louveau<sup>1\*</sup>, Mimi-Caterina Turtulici<sup>1</sup>, Angèle Consoli<sup>2,3</sup>,  
Christine Poitou<sup>4</sup>, Muriel Coupaye<sup>4</sup>, Marie-Odile Krebs<sup>1,5</sup>,  
Boris Chaumette<sup>1,5,6</sup> and Anton Iftimovici<sup>1,5\*</sup>

<sup>1</sup>Centre de Référence pour les Maladies Rares à expression Psychiatrique, GHU Paris Psychiatrie et Neurosciences, Paris, France, <sup>2</sup>Department of Child and Adolescent Psychiatry, Pitié-Salpêtrière Hospital, Paris, France, <sup>3</sup>GRC-15, Dimensional Approach of Child and Adolescent Psychotic Episodes, Faculté de Médecine, Sorbonne Université, Paris, France, <sup>4</sup>Nutrition Department, Rare Diseases Center of Reference "Prader-Willi Syndrome and Obesity With Eating Disorders" (PRADORT), Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière Hospital, INSERM, Nutriomics, Sorbonne Université, Paris, France, <sup>5</sup>Institute of Psychiatry and Neuroscience of Paris (IPNP), INSERM U1266, Université Paris Cité, Paris, France, <sup>6</sup>Department of Psychiatry, McGill University, Montréal, QC, Canada

## KEYWORDS

Prader-Willi, topiramate, treatment, genetics, deletion, disomy, personalized medicine

## A corrigendum on

### Prader-Willi syndrome: Symptoms and topiramate response in light of genetics

by Louveau, C., Turtulici, M.-C., Consoli, A., Poitou, C., Coupaye, M., Krebs, M.-O., Chaumette, B., and Iftimovici, A. (2023). *Front. Neurosci.* 17:1126970. doi: 10.3389/fnins.2023.1126970

In the published article, an author name was incorrectly written as Turtuluci. The correct spelling is Turtulici.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

## Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.